Vision 3 Local Codes

The following SNOMED CT codes do not map to existing Read codes, Cegedim Healthcare Solutions have therefore created Vision 3 Local Codes, based on the Read code format, to enable you to both record and report on these new codes within Vision 3:

Note - Removed terms display in both the release they are removed in and in the original release list, highlighted in red, with removal release details in the Release column.

Latest Release

SNOMED CT 36.2

New Vision Local Terms

SNOMED CT Code

Description

Vision Local Code

Keyword(s)

Release

871898007 Administr live attenuated Human alphaherpesvirus 3 vaccine 65FY300 SHINGLESVAC 36.2
698689005 ADHD predominantly inattentive type in remission E2E0200 ADHDREMISS

36.2

698692009 ADHD predominantly hyperactive type in remission E2E0300 ADHDREMISS 36.2
1464561000000107 Provision of CGM (continuous glucose monitoring) system 8O1F.00 CGM 36.2
1751131000000107 Valproate therapy stopped 8B3R000 VALPROATE 36.2
1326571000000106 Allergy to bempedoic acid 1Z44.00 BEMPEDOIC 36.2
1326121000000101 Allergy to ezetimibe 1Z45.00 EZETIMIBE 36.2
1362871000000100 Allergy to inclisiran 1Z46.00 INCLISIRAN 36.2
1326141000000108 Allergy to proprotein convertase subtilisin/kexin type 9 inhibitor 1Z47.00 PCSK9 36.2
1365431000000106 Allergy to alirocumab 1Z48.00 ALIROCUMAB 36.2
1365331000000104 Allergy to evolocumab 1Z49.00 EVOLOCUMAB 36.2
1365411000000103 Alirocumab contraindicated 8I2C000 ALIROCUMAB 36.2
1326611000000102 Bempedoic acid contraindicated 8I2C100 BEMPEDOIC 36.2
1326711000000108 Ezetimibe contraindicated 8I2C200 EZETIMIBE 36.2
1556841000000104 Icosapent ethyl contraindicated 8I2C300 ICOSAPENT 36.2
1362051000000103 Inclisiran contraindicated 8I2C400 INCLISIRAN 36.2
1326751000000107 Proprotein convertase subtilisin/kexin type 9 inhibitor contraindicated 8I2C500 PCSK9 36.2
1365371000000102 Evolocumab contraindicated 8I2C600 EVOLOCUMAB 36.2
1556871000000105 Icosapent ethyl declined 8I3J000 ICOSAPENT 36.2
1365381000000100 Evolocumab declined 8I3J100 EVOLOCUMAB 36.2
1365421000000109 Alirocumab declined 8I3J200 ALIROCUMAB 36.2
1326631000000105 Bempedoic acid refused 8I3J300 BEMPEDOIC 36.2
1326721000000102 Ezetimibe refused 8I3J400 EZETIMIBE 36.2
1362061000000100 Inclisiran refused 8I3J500 INCLISIRAN 36.2
1326761000000105 Proprotein convertase subtilisin/kexin type 9 inhibitor refused 8I3J600 PCSK9 36.2
1326601000000104 Bempedoic acid not indicated 8I69000 BEMPEDOIC 36.2
1326701000000106 Ezetimibe not indicated 8I69100 EZETIMIBE 36.2
1556881000000107 Icosapent ethyl not indicated 8I69200 ICOSAPENT 36.2
1362041000000101 Inclisiran not indicated 8I69300 INCLISIRAN 36.2
1365401000000100 Alirocumab not indicated 8I69400 ALIROCUMAB 36.2
1326741000000109 Proprotein convertase subtilisin/kexin type 9 inhibitor not indicated 8I69500 PCSK9 36.2
1365361000000109 Evolocumab not indicated 8I69600 EVOLOCUMAB 36.2
1464551000000109 Provision of intermittently scanned minimally-invasive interstitial fluid continuous glucose monitoring system 8O1E.00 FLASH 36.2
1326581000000108 Adverse reaction to bempedoic acid TJC2600 BEMPEDOIC 36.2
1326131000000104 Adverse reaction to ezetimibe TJC2700 EZETIMIBE 36.2
1556861000000103 Adverse reaction to icosapent ethyl TJC2800 ICOSAPENT 36.2
1362881000000103 Adverse reaction to inclisiran TJC2900 INCLISIRAN 36.2
1326151000000106 Adverse reaction to PCSK-9 inhibitor TJC2A00 PCSK9 36.2
1365441000000102 Adverse reaction to alirocumab TJC2B00 ALIROCUMAB 36.2
1365341000000108 Adverse reaction to evolocumab TJC2C00 EVOLOCUMAB 36.2

Removed Vision Local Codes

SNOMED CT Code

Description

Vision Local Code

Keyword(s)

Original Release

954008 Renon-Delille Syndrome C185.00   April 2018

Previous releases

Select a release to expand:

Note - To print this topic select Print in the top right corner and follow the on-screen prompts.